SEC 13F Intelligence

Nantahala Capital Management, LLC / KROS

Nantahala Capital Management, LLC’s Keros Therapeutics Inc Position

Does Nantahala Capital Management, LLC own Keros Therapeutics Inc (KROS)? Yes — 1.36M shares worth $15M (+0.55% of its 13F portfolio) as of Q1 2026, up from 360.4K shares the prior filed quarter.

Position Value
$15M
Q1 2026
Shares
1.36M
% of Portfolio
+0.55%
Quarters Held
24
currently held

Position History KROS

Reported value by quarter
Q2 ’20: $10MQ2 ’20Q3 ’20: $11MQ4 ’20: $38MQ1 ’21: $28MQ1 ’21Q2 ’21: $25MQ3 ’21: $30MQ4 ’21: $47MQ4 ’21Q1 ’22: $44MQ2 ’22: $25MQ3 ’22: $32MQ3 ’22Q4 ’22: $38MQ1 ’23: $32MQ2 ’23: $20MQ2 ’23Q3 ’23: $10MQ4 ’23: $25MQ1 ’24: $19MQ1 ’24Q2 ’24: $35MQ3 ’24: $22MQ4 ’24: $14MQ4 ’24Q1 ’25: $15MQ2 ’25: $22MQ3 ’25: $20MQ3 ’25Q4 ’25: $7MQ1 ’26: $15Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.36M$15M+0.55%
Q4 2025360.4K$7M+0.24%
Q3 20251.23M$20M+0.68%
Q2 20251.62M$22M+0.85%
Q1 20251.51M$15M+0.61%
Q4 2024915.0K$14M+0.62%
Q3 2024381.7K$22M+1.12%
Q2 2024757.6K$35M+1.02%
Q1 2024294.0K$19M+1.11%
Q4 2023620.3K$25M+0.74%
Q3 2023328.8K$10M+0.90%
Q2 2023497.2K$20M+1.93%
Q1 2023742.8K$32M+2.43%
Q4 2022792.1K$38M+2.47%
Q3 2022845.7K$32M+2.06%
Q2 2022911.9K$25M+1.26%
Q1 2022816.8K$44M+1.97%
Q4 2021796.7K$47M+1.64%
Q3 2021760.4K$30M+0.95%
Q2 2021598.9K$25M+0.72%
Q1 2021460.4K$28M+0.83%
Q4 2020534.5K$38M+1.17%
Q3 2020276.8K$11M+0.33%
Q2 2020275.0K$10M+0.31%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Nantahala Capital Management, LLC’s full portfolio or all institutional holders of KROS.